Oxford-AstraZeneca Coronavirus Vaccine Approved for Use in UK

Desk Report

Published: 30 Dec 2020, 02:07 pm

The coronavirus vaccine designed by scientists at Oxford University has been approved for use in the United Kingdom.

It marks a major turning point and will lead to a massive expansion of the UK immunization campaign, which aims to bring life back to normal, reports BBC.

The UK has ordered 100 million doses from manufacturer AstraZeneca-sufficient to vaccinate 50 million people.

The approval, by the medicines regulator, means the vaccine is both safe and effective.

The Oxford-AstraZeneca vaccine was designed in the first months of 2020, tested on the first volunteer in April, and has since undergone large-scale clinical trials involving thousands of people.

It was developed at a pace that would have been unthinkable before the pandemic.

It is the second Jab to be approved in the United Kingdom after Pfizer-BioNTech was given a go-ahead vaccine in December.

More than 600,000 people in the UK have been vaccinated since Margaret Keenan became the first person in the world to get that jab out of the clinical trial.

But the Oxford-AstraZeneca vaccine will lead to a significant increase in vaccination as it is cheap and easy to mass-produce.

Crucially it can be stored in a standard fridge - unlike the Pfizer-BioNTech jab which needs ultra cold storage at -70C - so it will be far easier to get the Oxford vaccine to care homes and GP surgeries.

Priority groups for immunisation - including the elderly, care home residents, and health and care workers - have already been identified.

The new vaccine approval comes after Public Health England said the country was facing "unprecedented" levels of infections, and health officials in parts of Wales, Scotland and the south of England voiced concerns about the increasing pressure on the NHS.

How does it work?

The vaccine is a genetically modified common cold virus that used to infect chimpanzees.

It has been altered to stop it from causing infection in humans and to carry a blueprint for part of the coronavirus, known as the spike protein.

Once these blueprints are inside the body, they start producing the coronavirus spike protein that the immune system recognizes as a threat and tries to squash.

Then, when the immune system comes into contact with the virus for real, it already knows what to do.

Editor & Publisher: Eliash Uddin Palash

Address: 10/22 Iqbal Road, Block A, Mohammadpur, Dhaka-1207

Design & Developed By Root Soft Bangladesh